FDA grants accelerated approval for J&J's RYBREVANT FASPRO in head and neck squamous cell carcinoma

Johnson & Johnson announced the FDA granted accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.

Detected & updated continuously · Source: Nebula